# A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer

> **NCT02778126** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 6 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** [¹⁴C]Prexasertib
- **DRUG:** Prexasertib

## Key facts

- **NCT ID:** NCT02778126
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-22
- **Primary completion:** 2017-04-29
- **Final completion:** 2017-07-27
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2019-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02778126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02778126, "A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02778126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*